Related Experiment Videos
99mTc-DTPA(Sn) dry-kit preparation. Quality control and clearance studies
Nuclear-Medizin
|January 31, 1975
Summary
Optimal preparation of technetium-99m diethylenetriaminepentaacetic acid (99m-Tc-DTPA) involves specific concentrations of DTPA and tin(II). This radiopharmaceutical demonstrates excellent correlation with creatinine clearance, making it valuable for renovascular imaging.
Area of Science:
- Nuclear Medicine
- Radiopharmaceutical Chemistry
- Clinical Chemistry
Background:
- Diethylenetriaminepentaacetic acid (DTPA) is a chelating agent used in nuclear medicine.
- Technetium-99m (99m-Tc) is a widely used radioisotope for diagnostic imaging.
- The development of stable 99m-Tc labeled radiopharmaceuticals is crucial for effective medical imaging.
Purpose of the Study:
- To determine the optimal preparation conditions for 99m-Tc-DTPA(Sn).
- To evaluate the pharmacokinetic properties and radiation dosimetry of 99m-Tc-DTPA(Sn).
- To assess the clinical utility of 99m-Tc-DTPA(Sn) for renovascular imaging.
Main Methods:
- Studied the effect of DTPA and Sn(II) concentrations on labeling yield.
- Prepared a sterile kit containing DTPA and SnCl2·2H2O.
- Administered 99m-Tc-DTPA(Sn) to human subjects and collected blood samples for plasma clearance analysis.
- Calculated absorbed radiation dose to various organs.
Main Results:
- Optimal labeling achieved with DTPA ≥ 10 mM and Sn(II) < 1 mM.
- Plasma clearance of 99m-Tc-DTPA(Sn) correlated well with endogenous creatinine clearance (r=0.93).
- Plasma disappearance exhibited a tri-exponential curve with biological half-lives of 18 min, 105 min, and 17 h; the latter component (2%) attributed to protein binding.
Conclusions:
- The optimized preparation yields a stable and reproducible 99m-Tc-DTPA(Sn) complex.
- 99m-Tc-DTPA(Sn) is a suitable agent for assessing renal function and renovascular diseases.
- The radiopharmaceutical allows for scintigraphic imaging of the aorta, kidneys, ureters, and bladder.